GO:0001905 activation of membrane attack complex: Complement Cytolysis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001905 activation of membrane attack complex describes the terminal step of the complement cascade in which C5b, C6, C7, C8 and multiple C9 molecules assemble into a pore-forming complex on a target membrane.
• The membrane attack complex (MAC) is a ~1-2 MDa ring-shaped pore that can directly lyse Gram-negative bacteria and nucleated cells, and it also triggers non-lytic signaling such as NLRP3 inflammasome activation and IL-1beta secretion.
• MAC assembly is spatially and temporally controlled: C5b-7 inserts into the membrane, C8 anchors the complex, and C9 monomers unfold and polymerize into a beta-barrel pore.
• Host cells are protected from accidental lysis by soluble and membrane-bound inhibitors, most notably CD59, which binds C8 and C9 and blocks C9 polymerization.
• Dysregulated MAC activity contributes to autoimmune hemolytic anemias, paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, neurodegeneration and inflammatory tissue injury, making the pathway a major therapeutic target.
• CRISPR knockout, point-mutation, knock-in and overexpression cell models of C5, C6, C7, C8, C9 and CD59 enable causal dissection of MAC biology and support drug discovery.
Description
The membrane attack complex (MAC), also called the terminal complement complex (TCC), is the cytotoxic effector of the complement cascade. GO:0001905 activation of membrane attack complex is the biological process in which the terminal complement components C5b, C6, C7, C8 and C9 assemble on a target membrane to form a pore that can kill the target cell by cytolysis. This process is the final common pathway of complement activation and is therefore a central node in innate immunity against Gram-negative bacteria and in antibody-dependent cytotoxicity. Because MAC assembly is a multi-step, membrane-dependent polymerization reaction, it is studied with structural biology, single-molecule imaging, complement assays and genetically engineered cell models. Mechanistically, activation of the membrane attack complex begins when C5 convertase cleaves C5, exposing a metastable binding site in C5b that captures C6 and C7. The resulting C5b-7 complex inserts into the lipid bilayer, recruits C8, and then templates the unfolding and polymerization of multiple C9 molecules into a transmembrane beta-barrel pore. The assembled MAC is a large ring-like structure whose dimensions and stoichiometry have been defined by cryo-electron microscopy and biochemical studies. Beyond direct lysis, sublytic MAC deposition activates signaling cascades, including the NLRP3 inflammasome and IL-1beta release in human macrophages, linking GO:0001905 to sterile inflammation and tissue injury. Host cells restrain MAC by membrane inhibitors such as CD59 and by soluble chaperones that package the soluble MAC for clearance. This balance between assembly and inhibition determines whether complement activation resolves an infection or damages host tissue, and it is the rationale for therapeutic inhibitors of C5 and C9.
activation of membrane attack complex At A Glance
| GO ID | GO:0001905 |
|---|---|
| GO term | activation of membrane attack complex |
| Ontology | biological_process |
| Synonyms | activation of MAC; activation of TCC; activation of terminal complement complex; activation of the terminal complement cascade; MAC assembly; MAC formation; membrane attack complex assembly; membrane attack complex formation |
| Major function | Assembly of C5b, C6, C7, C8 and C9 into a pore-forming complex that lyses target cells and generates sublytic signals |
| Cellular location | Target cell plasma membrane; soluble MAC can also be released into plasma |
| Key components | C5b, C6, C7, C8 (alpha, beta, gamma), C9, CD59, clusterin and vitronectin |
| Upstream activators | Classical, lectin and alternative complement pathways converging on C5 convertase |
| Main inhibitors | CD59, clusterin, vitronectin and engineered miniproteins targeting C9 |
| Disease relevance | PNH, autoimmune hemolytic anemia, AMD, neurodegeneration, ischemia-reperfusion injury and inflammatory disease |
What Is GO:0001905?
GO:0001905 activation of membrane attack complex is the biological process in which the terminal components of the complement cascade assemble into the membrane attack complex, a pore-forming structure that can cause death of a target cell through cytolysis. The process includes the generation of C5b, its association with C6, C7, C8 and C9, insertion into the target membrane, and C9 polymerization to form the lytic pore.
Why Is activation of membrane attack complex Important in Cell Biology?
GO:0001905 activation of membrane attack complex is important because it is the terminal effector of all complement activation routes and therefore a decisive determinant of target cell fate. It provides direct antimicrobial defense against Gram-negative bacteria, mediates antibody-dependent cytolysis, and, when dysregulated, drives host tissue damage in autoimmune, inflammatory and degenerative diseases. Structural and mechanistic studies of MAC assembly have revealed how C5b-8 templates C9 polymerization and how inhibitors such as CD59 and clusterin prevent accidental lysis, providing a blueprint for therapeutic blockade of the pathway. Because MAC also triggers non-lytic signaling such as NLRP3 inflammasome activation, the process is relevant to sterile inflammation and cytokine-driven pathology beyond simple cytolysis. Finally, the pathway is a validated drug target, and C5- and C9-directed inhibitors are in clinical or preclinical development, making precise genetic models of MAC components highly valuable.
• Provides the lytic effector mechanism of complement against Gram-negative bacteria and antibody-coated target cells.
• Links innate immunity to inflammation through sublytic MAC-induced NLRP3 inflammasome activation and IL-1beta secretion.
• Dysregulated MAC causes paroxysmal nocturnal hemoglobinuria and other complement-mediated hemolytic anemias.
• MAC deposition contributes to age-related macular degeneration and retinal degeneration.
• MAC-mediated injury is implicated in ischemia-reperfusion injury, transplant rejection and neurodegeneration.
• CD59 deficiency in humans causes complement-mediated hemolysis and neuropathy, illustrating the need for tight MAC control.
• Soluble MAC is packaged for clearance by chaperones, revealing a quality-control layer in the terminal pathway.
• Structural knowledge of C5b-8 and C9 polymerization supports rational design of MAC inhibitors.
• Miniprotein inhibitors of C9 can block MAC assembly, demonstrating druggability of the terminal step.
• CRISPR-engineered cell models of C5-C9 and CD59 enable causal testing of MAC function in disease.
What Happens During activation of membrane attack complex?
Initiation by C5 convertase and generation of C5b
In simple terms: The complement cascade cuts C5 into C5b, which is the seed that starts the pore.
Activation of the membrane attack complex begins when any of the three complement pathways generates a C5 convertase that cleaves C5. The cleavage exposes a transient binding site in C5b that can capture C6, committing the complex to MAC assembly. This step is the point of convergence of classical, lectin and alternative complement activation and is a major target of therapeutic antibodies and small molecules.
Formation and membrane insertion of C5b-7
In simple terms: C5b grabs C6 and C7, and this trio inserts into the target cell membrane.
C5b binds C6 to form C5b-6, which then associates with C7. The C5b-7 complex exposes a hydrophobic site that inserts into the lipid bilayer of the target membrane. Structural studies show that C6 and C7 are the key membrane-inserting subunits that anchor the growing complex and define the site of pore formation.
Recruitment of C8 and formation of the C5b-8 template
In simple terms: C8 joins the complex and starts to make a small hole in the membrane.
Membrane-bound C5b-7 recruits C8, a three-chain protein (alpha, beta, gamma). The C8 beta chain inserts into the bilayer and, together with C5b-7, forms the C5b-8 complex that serves as the template for C9 polymerization. Cryo-electron microscopy of C5b-8 has revealed how the complex primes the membrane for C9 addition and how CD59 can block this step.
C9 polymerization and pore formation
In simple terms: Many C9 molecules unfold and stack into a ring that punches a hole in the membrane.
C5b-8 catalyzes the unfolding and sequential addition of multiple C9 monomers, which polymerize into a beta-barrel ring that forms the transmembrane pore. The resulting MAC is a large, ring-shaped complex whose stoichiometry and dimensions have been characterized biochemically and structurally. C9 polymerization is the step most directly responsible for cytolysis and is targeted by inhibitory miniproteins.
Lytic and sublytic outcomes
In simple terms: The pore can either kill the cell directly or send inflammatory signals.
Fully assembled MAC pores cause osmotic lysis and death of the target cell. At sublytic doses, MAC deposition activates signaling pathways, including the NLRP3 inflammasome and IL-1beta secretion in human macrophages, thereby amplifying inflammation. This duality explains why MAC is relevant both to antimicrobial defense and to sterile inflammatory disease.
Inhibition and clearance of the complex
In simple terms: The body has brakes that stop the pore from forming and clear away the pieces.
CD59 binds C8 and C9 and prevents C9 polymerization, protecting host cells from accidental lysis. Soluble forms of the complex are packaged by chaperones such as clusterin and vitronectin for clearance, a process whose structural basis has been resolved. These inhibitory layers are essential for self-tolerance and are being exploited for therapeutic MAC blockade.
Key Genes Involved in GO:0001905 activation of membrane attack complex
The genes encoding terminal complement components, their receptors and their inhibitors define the molecular machinery of GO:0001905 activation of membrane attack complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| C5 | Source of C5b, the seed of MAC assembly after cleavage by C5 convertase | Knockout and point-mutation models to dissect C5 activation and drug binding |
| C6 | Binds C5b and is required for membrane insertion of the C5b-7 complex | KO cells to test C6-dependent MAC formation and bacterial killing |
| C7 | Associates with C5b-6 and inserts into the membrane, anchoring the complex | KO and tagged knock-in to track C5b-7 assembly |
| C8A | Alpha chain of C8, part of the C5b-8 template for C9 polymerization | KO to block C9 recruitment and study sublytic signaling |
| C8B | Beta chain of C8 that inserts into the membrane | Point mutations to map membrane-insertion residues |
| C8G | Gamma chain of C8, stabilizes the C8 heterotrimer | KO to assess C8 assembly and MAC activity |
| C9 | Polymerizes into the beta-barrel pore that lyses target cells | KO, point-mutation and overexpression models for pore formation |
| CD59 | GPI-anchored inhibitor that blocks C8 and C9, preventing pore formation | KO and knock-in to study protection from complement lysis |
| CLU (clusterin) | Soluble chaperone that packages MAC for clearance | KO and overexpression to study soluble MAC handling |
| VTN (vitronectin) | Soluble inhibitor that binds C5b-7 and blocks membrane insertion | KO to test soluble MAC regulation |
| C3 | Upstream complement component required for C5 convertase generation | KO to abolish all downstream MAC formation |
| CFB | Alternative pathway factor B, contributes to C5 convertase | KO to isolate alternative pathway-driven MAC |
| C4 | Classical and lectin pathway component upstream of C5 convertase | KO to isolate classical pathway-driven MAC |
| CFH | Complement factor H, regulates alternative pathway C3 convertase | KO and point mutations to model complement dysregulation |
| CFI | Complement factor I, cleaves C3b and regulates convertase activity | KO to study uncontrolled complement activation |
| NLRP3 | Inflammasome sensor activated by sublytic MAC | KO to test MAC-driven IL-1beta secretion |
| CASP1 | Caspase-1, executes inflammasome-dependent cytokine maturation downstream of MAC | KO to link MAC to IL-1beta release |
| IL1B | Cytokine secreted after MAC-induced inflammasome activation | Reporter knock-in to quantify sublytic MAC signaling |
How Is activation of membrane attack complex Regulated?
Activation of the membrane attack complex is regulated at multiple levels. Upstream, complement activation is controlled by convertase regulators such as factor H and factor I, which determine how much C5 convertase is available to initiate MAC assembly. At the terminal step, CD59 binds C8 and C9 and directly blocks C9 polymerization, providing species-specific protection of host membranes. Soluble chaperones including clusterin and vitronectin capture nascent C5b-7 and soluble MAC, packaging them for clearance and preventing bystander lysis. In addition, sublytic MAC signaling is modulated by inflammasome components such as NLRP3 and caspase-1, which convert membrane deposition into cytokine output. Therapeutic regulation is also possible: engineered miniproteins targeting C9 can block MAC assembly, illustrating that the terminal step is druggable.
activation of membrane attack complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD59 | Paroxysmal nocturnal hemoglobinuria and complement-mediated hemolysis | CD59 knockout and GPI-anchor-deficient cell lines |
| C5 | Complement-mediated hemolytic anemia and inflammatory disease | C5 knockout and point-mutation cells for inhibitor testing |
| C9 | MAC-driven cytolysis and Neisseria susceptibility | C9 knockout and overexpression models for pore formation |
| NLRP3 | Sterile inflammation downstream of sublytic MAC | NLRP3 knockout macrophages with MAC deposition |
| CLU | Soluble MAC clearance and protein aggregation disease | Clusterin knockout and tagged knock-in cells |
Complement-mediated hemolytic diseases
Inflammatory and neurodegenerative disease
Infection and host defense
From activation of membrane attack complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of C9 abolish MAC pore formation and cytolysis? | |
| Which residues in C8B mediate membrane insertion? | |
| How does CD59 block C9 polymerization at the membrane? | |
| Can a disease-associated C5 variant alter convertase cleavage? | |
| How does sublytic MAC activate the NLRP3 inflammasome? | |
| Can C9-targeting miniproteins block MAC assembly in cells? |
How to Study the activation of membrane attack complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CH50/AH50 hemolytic assay | Total complement lytic activity | Diagnosis of complement deficiencies and inhibitor testing |
| Soluble C5b-9 ELISA | Amount of soluble terminal complement complex | Monitoring complement activation in plasma |
| Flow cytometry for membrane C5b-9 | MAC deposition on target cell surfaces | Quantifying activation of membrane attack complex in vitro |
| Cryo-electron microscopy | Three-dimensional structure of MAC assembly intermediates | Mechanistic studies of C5b-8 and C9 polymerization |
| CRISPR knockout screens | Genes required for MAC-mediated lysis or signaling | Discovery of regulators of GO:0001905 |
| Inflammasome assays | NLRP3 activation, caspase-1 cleavage and IL-1beta release | Linking sublytic MAC to inflammation |
| Surface plasmon resonance | Binding affinity of inhibitors to C5, C8 or C9 | Characterizing MAC-blocking biologics |
| Live-cell imaging | Real-time pore formation and membrane integrity | Visualizing MAC assembly dynamics |
Complement activation and MAC deposition assays
Structural biology of MAC assembly
Genetic and CRISPR-based perturbation
Signaling and inflammasome readouts
How CRISPR Can Be Used to Study GO:0001905 activation of membrane attack complex
Knockout
Point Mutation
Knock-in
Overexpression
How EDITGENE Supports activation of membrane attack complex Research
Researchers studying activation of membrane attack complex-related genes often need to determine whether a candidate gene is causally involved in MAC assembly, regulation or downstream signaling, rather than merely correlated with complement activation. EDITGENE provides publication-grade CRISPR cell models and screening services that let you move from hypothesis to mechanism with isogenic, validated clones.
Contact EDITGENE today to design your custom CRISPR model for activation of membrane attack complex research.
Frequently Asked Questions About activation of membrane attack complex
What is activation of membrane attack complex (GO:0001905)?
It is the biological process in which complement components C5b, C6, C7, C8 and C9 assemble into a pore-forming complex on a target membrane, potentially causing cell death by cytolysis.
What genes are involved in activation of membrane attack complex?
The core genes are C5, C6, C7, C8A, C8B, C8G and C9, with regulators such as CD59, CLU and VTN controlling the process.
How is the membrane attack complex assembled?
C5 cleavage generates C5b, which binds C6 and C7, inserts into the membrane, recruits C8 and then templates C9 polymerization into a beta-barrel pore.
What is the role of C9 in MAC formation?
C9 monomers unfold and polymerize into the transmembrane pore that lyses target cells, making C9 the key effector of GO:0001905.
How does CD59 inhibit the membrane attack complex?
CD59 binds C8 and C9 and blocks C9 polymerization, protecting host cells from complement-mediated lysis.
What diseases are linked to membrane attack complex dysregulation?
Paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, age-related macular degeneration, neurodegeneration and inflammatory tissue injury are associated with dysregulated MAC activity.
Does the membrane attack complex only cause cell lysis?
No. Sublytic MAC deposition activates the NLRP3 inflammasome and IL-1beta secretion, linking GO:0001905 to sterile inflammation.
How can I study activation of membrane attack complex in the lab?
Common approaches include hemolytic assays, soluble and membrane C5b-9 detection, cryo-electron microscopy, CRISPR knockout models and inflammasome readouts.
What is the difference between MAC and TCC?
MAC (membrane attack complex) and TCC (terminal complement complex) are synonyms for the same C5b-9 assembly, and both terms are listed for GO:0001905.
Can CRISPR be used to model MAC-related disease?
Yes. Knockout, point-mutation, knock-in and overexpression models of C5-C9 and CD59 allow causal testing of MAC function and inhibitor response.
Conclusion
GO:0001905 activation of membrane attack complex captures the terminal, pore-forming step of complement that determines whether a target cell is lysed or receives inflammatory signals. Structural and genetic studies have defined the assembly pathway from C5b-7 through C5b-8 to the C9 pore, and have revealed how inhibitors such as CD59 and clusterin keep the system in check. Because dysregulated MAC activity underlies hemolytic, inflammatory and degenerative diseases, the pathway is a major therapeutic target and a rich area for CRISPR-based mechanistic research. For researchers, the combination of isogenic knockout, point-mutation, knock-in and overexpression cell models with functional complement assays provides a rigorous route to establish causality for candidate genes in the terminal complement pathway. EDITGENE supports this workflow with validated CRISPR models, library screening and bioinformatics tailored to activation of membrane attack complex biology.
References
- 1. Xie CB et al.. 2020. Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets.. Am J Pathol 190(6):1138-1150 PMID: 32194049
- 2. Couves EC et al.. 2023. Structural basis for membrane attack complex inhibition by CD59.. Nat Commun 14(1):890 PMID: 36797260
- 3. Menny A et al.. 2021. Structural basis of soluble membrane attack complex packaging for clearance.. Nat Commun 12(1):6086 PMID: 34667172
- 4. Sonnen AF et al.. 2014. Structural biology of the membrane attack complex.. Subcell Biochem 80:83-116 PMID: 24798009
- 5. Li M et al.. 2026. Design of miniprotein inhibitors targeting complement C9 to block membrane attack complex assembly.. Nat Commun 17(1) PMID: 41813685
- 6. Diaz-Del-Olmo I et al.. 2021. Internalization of the Membrane Attack Complex Triggers NLRP3 Inflammasome Activation and IL-1β Secretion in Human Macrophages.. Front Immunol 12:720655 PMID: 34650553
- 7. Esser AF. 1994. The membrane attack complex of complement. Assembly, structure and cytotoxic activity.. Toxicology 87(1-3):229-47 PMID: 8160186
- 8. Serna M et al.. 2016. Structural basis of complement membrane attack complex formation.. Nat Commun 7:10587 PMID: 26841837
